Jim Cramer: Novocure, Veru, and Regeneron - Buy, Sell, or Hold

Jim Cramer has some thoughts on Regeneron  (REGN) - Get Report, Veru  (VERU) - Get Report, and Novocure  (NVCR) - Get Report. He gives investors his thoughts on each stock as a buy, sell, or hold. 

And this comes after a committee reviewed the Phase 3 trial of Novocure's lung cancer treatment candidate.

The independent data monitoring committee said the interim results of the trial of Novocure's tumor-treating fields should be accelerated. The TTFs are electric fields designed to disrupt cell division in stage 4 non-small-cell lung cancer.

The panel's recommendations "support the potential for TTFields to make a significant difference in treatment outcomes for patients with non-small-cell lung cancer, whether used together with immune checkpoint inhibitors or docetaxel,” Novocure executive chairman William Doyle said in a statement.

And Regeneron's COVID-19 cocktail shows promise as a preventative treatment. 

The company's Phase 3 trial gave the drug to "recently infected" people who were asymptomatic.

"Regen-COV reduced the overall risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day," Regeneron said in a statement.

Regeneron said it will ask the U.S. Food and Drug Administration to expand the drug's authorization among people exposed to the virus who haven't yet been vaccinated. 

Watch TheStreet Live: Everything Jim Cramer Is Watching Tuesday.

You can follow Jim Cramer and Katherine Ross on Twitter at @JimCramer and @byKatherineRoss. Read more from Katherine Ross here.